ストックスクリーナーアプリを入手
1.88
9.94%
0.17
アフターアワーズ：
1.82
-0.06
-3.19%
前日終値:
$1.71
開ける：
$1.72
24時間の取引高:
70,217
Relative Volume:
0.94
時価総額：
$2.87M
収益：
-
当期純損益:
$-23.14M
株価収益率:
-1.8557
EPS:
-1.0131
ネットキャッシュフロー:
$-29.23M
1週間 パフォーマンス:
-23.27%
1か月 パフォーマンス:
-65.00%
6か月 パフォーマンス:
-78.86%
1年 パフォーマンス:
-83.78%
1日の値動き範囲:
$1.70
$1.91
1週間の範囲:
$1.5004
$2.535
52週間の値動き範囲:
$1.5004
$22.06
BiomX Inc Stock (PHGE) Company Profile
名前
BiomX Inc
セクター
電話
972 7 23942377
住所
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
PHGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
1.88 | 2.61M | 0 | -23.14M | -29.23M | -1.0131 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-04-15 | 開始されました | Ladenburg Thalmann | Buy |
BiomX Inc (PHGE) 最新ニュース
Can BiomX Inc. stock reach $100 price targetJuly 2025 EndofMonth & Safe Entry Zone Tips - Улправда
BiomX collapses into court proceedings after clinical trial fails - CTech
BiomX Discontinues Study and Files for Insolvency - TipRanks
BiomX Inc. Discontinues Phase 2b Study and Initiates Insolvency Proceedings - TradingView — Track All Markets
BiomX (NYSE: PHGE) subsidiary seeks insolvency as Phase 2b study ends, BX011 program retained - Stock Titan
BiomX Discontinues Phase 2b Trial for BX004 - The Globe and Mail
Healthy Upside Potential: BiomX Inc (PHGE) - setenews.com
BiomX Halts Phase 2b Trial Of BX004 In Cystic Fibrosis On High Rates Of Adverse Events - Nasdaq
Stocks Tumble As Bad News Hits Biotech And Energy Sectors - Finimize
BiomX Discontinues Phase 2b Clinical Trial for BX004 - TradingView
BiomX (PHGE) Halts Phase 2b Trial and Implements Cost-Saving Str - GuruFocus
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review - The Manila Times
BiomX announces discontinuation of phase 2b Bx004 trial following internal review - marketscreener.com
BiomX (NYSE American: PHGE) halts BX004 CF trial, to cut costs, weigh options - Stock Titan
BiomX discontinues phase 2b trial for BX004 - MSN
BiomX (PHGE) Price Target Increased by 964.52% to 168.30 - Nasdaq
BiomX (PHGE) Stock Analysis Report | Financials & Insights - Benzinga
Why BiomX Inc. stock could be top winner2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
How BiomX Inc. stock performs in high volatility marketsJuly 2025 Update & Daily Price Action Insights - Newser
How BiomX Inc. stock reacts to Fed tighteningJuly 2025 Update & AI Forecasted Entry/Exit Points - Newser
How BiomX Inc. stock compares with tech leadersJuly 2025 Review & Technical Pattern Alert System - Newser
How forex fluctuations impact BiomX Inc. stockWeekly Stock Recap & High Yield Equity Trading Tips - Newser
Is BiomX Inc. stock ideal for retirement investorsMarket Growth Report & Comprehensive Market Scan Reports - Newser
How BiomX Inc. stock behaves in tightening cyclesAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
BiomX provides update on BX004 Phase 2b trial in Cystic Fibrosis - MSN
BiomX announces 1-for-19 reverse stock split - MSN
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries - Investing.com Canada
HC Wainwright Issues Optimistic Estimate for BiomX Earnings - Defense World
BiomX (NYSEAMERICAN:PHGE) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
BiomX (NYSEAMERICAN:PHGE) Price Target Raised to $26.00 at HC Wainwright - Defense World
HC Wainwright Forecasts Strong Price Appreciation for BiomX (NYSEAMERICAN:PHGE) Stock - Defense World
HC Wainwright Boosts BiomX (NYSEAMERICAN:PHGE) Price Target to $26.00 - Defense World
HC Wainwright & Co. Reiterates BiomX (PHGE) Buy Recommendation - Nasdaq
PHGE: HC Wainwright & Co. Reiterates Buy Rating with $26 PT | PH - GuruFocus
Why Is BiomX Stock Falling Today?BiomX (AMEX:PHGE) - Benzinga
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review - Sahm
BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 - Nasdaq
BiomX Says Working to Lift FDA Hold Concerning Nebulizer Device in Phase 2b Study of BX004 for Cystic Fibrosis - marketscreener.com
FDA Review Delays BiomX's (PHGE) Cystic Fibrosis Trial Progress - GuruFocus
BiomX Updates on Phase 2b Study for BX004 - TipRanks
BiomX Updates on FDA Clinical Hold and Study Progress - TradingView
BiomX (NYSE American: PHGE) DMC Backs BX004 Phase 2b Study, Topline Expected 2026 - Stock Titan
PHGE: HC Wainwright Raises Price Target for BiomX to $26.00 | PH - GuruFocus
HC Wainwright & Co. Maintains BiomX (PHGE) Buy Recommendation - Nasdaq
BiomX price target adjusted to $26 from $15 at H.C. Wainwright - TipRanks
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis - Yahoo Finance
Stock splits calendar for: - Yahoo Finance Singapore
BiomX announces FDA feedback on development pathway for BX011 - MSN
BiomX Inc. Reports Q3 2025 Financial Results and Program Updates - MSN
BiomX Inc. Earnings Call: Progress Amid Challenges - MSN
BiomX Inc (PHGE) 財務データ
収益
当期純利益
現金流量
EPS
0.31%
0.33%
大文字化:
|
ボリューム (24 時間):